Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 1 |
2017 | 1 |
2019 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Biomarkers for severe eosinophilic asthma.
J Allergy Clin Immunol. 2017 Dec;140(6):1509-1518. doi: 10.1016/j.jaci.2017.10.005.
J Allergy Clin Immunol. 2017.
PMID: 29221581
Free article.
Review.
Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M, Albers FC, Bratton DJ, Yancey SW, Liu MC, Hozawa S, Llanos JP, Kwon N.
Humbert M, et al.
Respir Med. 2019 Jul-Aug;154:69-75. doi: 10.1016/j.rmed.2019.06.004. Epub 2019 Jun 8.
Respir Med. 2019.
PMID: 31220806
Free article.
Item in Clipboard
Engineering of genetic control tools in Synechocystis sp. PCC 6803 using rational design techniques.
Albers SC, Gallegos VA, Peebles CA.
Albers SC, et al.
J Biotechnol. 2015 Dec 20;216:36-46. doi: 10.1016/j.jbiotec.2015.09.042. Epub 2015 Oct 9.
J Biotechnol. 2015.
PMID: 26450561
Item in Clipboard
Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, Kwon N, Quirce S.
Albers FC, et al.
Respir Med. 2019 Nov;159:105806. doi: 10.1016/j.rmed.2019.105806. Epub 2019 Nov 3.
Respir Med. 2019.
PMID: 31751853
Free article.
Item in Clipboard
Cite
Cite